Xeris gains as Oppenheimer highlights drug technology [Seeking Alpha]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Seeking Alpha
Designed to deliver subcutaneous or intramuscular treatments instead of intravenous infusions, XeriSol and XeriJect allow for convenient, cost-effective drug storage, improving the overall healthcare experience. Oppenheimer analyst Leland Gershell notes that the company has already attracted partnerships from Regeneron ( REGN ) and Amgen ( AMGN ) with its XeriJect formulation, and more deals are likely on the horizon. Gershell argues that XeriJect has notable benefits compared to a similar technology from Halozyme ( HALO XERS's experimental therapy, XP-8121, based on XeriSol technology, is designed to overcome some of the key limitations in current hypothyroidism management. Topline data for XP-8121 in hypothyroidism, expected in mid-2024 from a mid-stage study, "will increase our confidence in this candidate's potential $1B+ sales opportunity and catalyze investor interest," the analyst wrote. Recommended For You More Trending News Recommended For You More Trending N
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Mahesh Krishnan Elected to Halozyme's Board of Directors [Yahoo! Finance]Yahoo! Finance
- Mahesh Krishnan Elected to Halozyme's Board of DirectorsPR Newswire
- Why This 1 Value Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- Halozyme to Report First Quarter 2024 Financial and Operating Results [Yahoo! Finance]Yahoo! Finance
- Halozyme to Report First Quarter 2024 Financial and Operating ResultsPR Newswire
HALO
Earnings
- 2/20/24 - Beat
HALO
Sec Filings
- 4/26/24 - Form 8-K
- 4/25/24 - Form 3
- 4/17/24 - Form 4
- HALO's page on the SEC website